# Head and Neck Cancer Pathways

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
</tbody>
</table>

**Pathology:**

<table>
<thead>
<tr>
<th>Line of Therapy:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Neoadjuvant/Pre-Op</em></td>
<td><em>Adjuvant/Post-Op</em></td>
<td></td>
</tr>
<tr>
<td><em>1st Line</em></td>
<td><em>2nd Line</em></td>
<td></td>
</tr>
</tbody>
</table>

**Non-Nasopharyngeal (Squamous Cell Carcinoma) | Candidate for Local Therapy (M0) | Primary Systemic Therapy or Post-Operative Systemic Therapy**

- [ ] High dose cisplatin* with concurrent RT

**Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | First Line of Therapy (1st line)**

- [ ] Carboplatin, fluorouracil (5FU), and cetuximab (Erbitux)
- [ ] Cisplatin, fluorouracil (5FU), and cetuximab (Erbitux)

**Non-Nasopharyngeal (Squamous Cell Carcinoma) | Metastatic and Recurrent Disease | Second and Subsequent Lines of Therapy (2nd line+)**

- [ ] Nivolumab (Opdivo)
- [ ] Paclitaxel

**Nasopharynx | Candidate for Local Therapy (M0) | Primary Systemic Therapy**

- [ ] High dose cisplatin* with concurrent RT
- [ ] Cisplatin and gemcitabine (Gemzar) followed by concurrent cisplatin/RT

**Nasopharynx | Metastatic and Recurrent Disease | First and Subsequent Lines of Therapy (1st Line+)**

- [ ] Carboplatin
- [ ] Cisplatin
- [ ] Cisplatin and gemcitabine (Gemzar)
- [ ] Cisplatin and paclitaxel
- [ ] Fluorouracil (5FU)
- [ ] Gemcitabine (Gemzar)
- [ ] Methotrexate
- [ ] Paclitaxel

*High dose cisplatin refers to dosing to achieve total dose of 200-300 mg/m² of cisplatin over the course of the radiotherapy. There are several different appropriate cisplatin schedules that may be used.

†Substitution of carboplatin for cisplatin, and vice-versa, is acceptable for metastatic disease.

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars of reference products listed are considered “on pathway.” However, reimbursement for biosimilar products may be impacted by health plan specific formularies, medical policy and preferred product rules.